Merimepodib

DB04862InvestigationalSmall molecule

Merimepodib (VX-497) is a novel noncompetitive inhibitor of IMPDH. Merimepodib is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100...

Mechanism: Merimepodib is a orally active inhibitor of inosine monophospate dehydrogenase (IMPDH). IMPDH inhibition leads to a reduction in intracellular guanosine triphosphate (GTP), a molecule required for DNA and RNA synthesis.
Curator reviewed
Primary indication: For the treatment of hepatitis C virus (HCV) infection.Curator reviewed
Formula / weight: C₂₃H₂₄N₄O₆ · 452.4599 g/mol (avg)
Code names: VI-21,497 · VX-497

Resolves to

Compound

UNII2ZL2BA06FUCAS198821-22-6ChEMBLCHEMBL304087PubChem153241

Structure

InChIKeyJBPUGFODGPKTDW-SFHVURJKSA-NSMILESCOC1=C(C=CC(NC(=O)NC2=CC=CC(CNC(=O)O[C@H]3CCOC3)=C2)=C1)C1=CN=CO1

Targets

P20839IMPDH1P00533EGFRP04626ERBB2P0C0H6guaB

What you can answer from here — as of June 15, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Merimepodib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account